The 2026 AMCP Annual Meeting made one thing clear. Managed care pharmacy is in the middle of a structural shift. Specialty drug growth, strained utilization management, GLP-1 formulary pressure, and a maturing AI conversation all dominated the agenda. Here is what mattered most.
1. Specialty Drugs Are No Longer a Category. They Are the Market.
Oncology, biologics, and emerging specialty therapies dominated sessions and hallway conversations alike. This is no longer a trend to monitor. Specialty is pharmacy spend. Plans still managing it in silos, separate from medical benefits, are already behind.
2. Traditional Utilization Management Is Buckling.
Prior authorization and formulary management were examined through a sustainability lens, not a compliance one. The message was blunt. Traditional UM tools cannot keep pace with therapies that are increasingly targeted, expensive, and patient-specific. Plans need a better approach.
3. GLP-1s Are a Formulary Flashpoint.
GLP-1 therapies surfaced across clinical, economic, and policy sessions. Presentations showed that formulary switches, even well-intentioned ones, can cause serious short-term member disruption. This class is uniquely sensitive. Reactive decisions carry real cost for members and for plan performance.
4. AI Is Everywhere. Now, Governance Is the Real Work.
AI had a strong presence, including a dedicated pre-conference summit. The conversation has matured. Speakers focused on governance, explainability, and integration into existing workflows. The recommendation was consistent: disciplined, narrowly scoped adoption aligned to clear outcomes. Speed is not the goal. Trust is the goal and is harder to find.
The Bottom Line
These four forces are not isolated trends. They are converging. Plans that will lead are those that manage them together, not in silos. In Part 2, we outline the specific actions health plans and PBMs should take now.
